Plasmodium cynomolgi is a protozoan parasite that is closely related to Plasmodium falciparum, the causative agent of malaria. The antigens of P. cynomolgi can be used to diagnose infections in humans as well as for research purposes. These antigens include MSP1 (merozoite surface protein 1), MSP2 (merozoite surface protein 2), and AMA1 (apical membrane antigen 1). In addition to these, other antigens such as SERA (serine-rich repeat antigen), EBA (erythrocyte binding antigen), and RESA (ring-infected erythrocyte surface antigen) are also being studied and developed for use in diagnosis and research.

Circumsporozoite Protein CS is a protein that is produced by the Plasmodium Cynomolgi parasite during its sporozoite stage. This protein is located on the surface of the parasite and is believed to play a crucial role in the invasion of the parasite into the host’s liver cells.

Circumsporozoite Protein CS is a key focus of research into the development of new treatments and vaccines for malaria. By understanding the role of this protein in the life cycle of the Plasmodium Cynomolgi parasite, researchers hope to develop new drugs and vaccines that can prevent and treat malaria.

One area of research involves developing a vaccine that targets Circumsporozoite Protein CS. This vaccine would work by stimulating the body’s immune system to produce antibodies that can recognize and neutralize the protein, preventing the parasite from invading liver cells and causing malaria.

By understanding the biology of Circumsporozoite Protein CS and its role in the life cycle of the Plasmodium Cynomolgi parasite, researchers may be able to develop new drugs and vaccines that can target similar proteins in other Plasmodium species, ultimately leading to better prevention and treatment of malaria in humans.

Plasmodium cynomolgi cDNA and recombinant antigens can be used in several applications. One application is in the development of vaccines against malaria. The cDNA and antigens can be used to create a genetically engineered vaccine that can provide protection against the disease. Additionally, the cDNA and antigens can be used to develop diagnostic tests for malaria, as well as for therapeutic treatments. Finally, these cDNA and antigens can be used to study the genetics of malaria, which can help scientists to better understand how to prevent and treat it.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.